intoDNA Forms Strategic Advisory Board with Leading Diagnostics and Precision Oncology Experts
– New board to accelerate the STRIDE® platform, revolutionizing DNA damage and repair diagnostics for precision oncology –
KRAKÓW, POLAND, February 4, 2026 — intoDNA, a company pioneering functional biomarkers for precision medicine, today announced the formation of its Strategic Advisory Board (SAB), with members including Ranjit Bindra, MD, PhD; Mike Dillon, PhD; Anne-Renee Hartman, MD; Scott K. Pruitt, MD, PhD; Jane Theaker; and Timothy A. Yap, MBBS, PhD. With decades of combined experience spanning drug discovery, diagnostics development and precision oncology, the SAB will be a key asset as intoDNA accelerates product development and continues to scale its proprietary STRIDE® platform technology.
“We’re thrilled to announce the formation of the intoDNA Strategic Advisory Board, with such distinguished leaders in the life sciences as our founding members,” said Magda Kordon-Kiszala, PhD, Founder and CEO of intoDNA. “With proven track records of building robust oncology therapeutic pipelines and scaling precision oncology diagnostics, our Board will be an invaluable asset as we work to expand access to STRIDE®, our proprietary DNA break and repair detection technology. I’m confident that with their support, intoDNA is well positioned to continue advancing STRIDE as a leading tool for precision biomarker discovery and targeted oncology drug development.”
Strategic Advisory Board Members:
- Ranjit Bindra, MD, PhD – Harvey and Kate Cushing Professor of Therapeutic Radiology, Yale School of Medicine: Dr. Bindra is a physician-scientist and the Scientific Director of the Yale Brain Tumor Center. He leads four major laboratories at Yale, notably reporting that IDH1/2-mutant tumors harbor profound DNA repair defects sensitive to PARP inhibitors—work he is now translating into multiple clinical trials. An active biotech entrepreneur, Dr. Bindra has founded six companies based on his research. He holds an MD and PhD from the Yale School of Medicine and completed his residency at Memorial Sloan-Kettering Cancer Center.
- Mike Dillon, PhD – CTO at CuraSen Therapeutics: With more than 30 years of experience in large pharma and biotech, Dr. Dillon previously served as CSO at Modifi Bio (acquired by Merck in 2025) and as Head of Research at IDEAYA Biosciences. At IDEAYA, he helped establish the company as a leader in Synthetic Lethal Oncology with a focus on DNA Damage Response (DDR) therapeutics. He has also held leadership roles at Novartis Institutes for BioMedical Research and Roche. Dr. Dillon received his PhD at the University of Bristol and his BSc in Chemistry from the University of Leicester. He is an author of more than 70 publications and patents.
- Anne-Renee Hartman, MD – Co-founder and CMO at Adela: Dr. Hartman has 20 years of experience bringing innovative technologies to market. At Adela, she has raised over $130 million to advance methylation technology for early cancer detection. Widely recognized as an expert in liquid biopsy, she previously led clinical development at GRAIL and served as SVP of Clinical Development at Myriad Genetics, where she spearheaded the development of MyChoice CDx and BRACAnalysis CDx. Dr. Hartman received her AB from Princeton University and her MD from the University of Michigan. She completed her oncology fellowship at Stanford University and served as Assistant Professor of Medicine at Dana-Farber Cancer Institute.
- Scott K. Pruitt MD, PhD – Clinical and Translational Oncology Consultant: Dr. Pruitt recently retired from Merck, where he led Translational Oncology and served as Clinical Director for the pivotal Keynote-158 trial, contributing to seven FDA approvals for Keytruda. His work included pioneering efforts in digital pathology and AI diagnostics. Prior to Merck, Dr. Pruitt was a Surgical Oncologist at Duke University, where he led a translational science lab focused on tumor immunology. He earned his MD at Columbia University and his PhD in Microbiology and Immunology at Duke University.
- Jane Theaker – an experienced diagnostics expert, co-inventor of Scorpions primers, a director of SpinXperts Ltd and Chair at Invenirex Ltd.: Prior to these roles, Jane served as CEO at PBD Biotech Limited and as CEO at the spinout Kinomica. Jane served as CEO at PBD Biotech Limited and as CEO at the spinout Kinomica. She is a companion diagnostics expert having developed a technology that was later spun out and sold to Qiagen for $130M. She has developed numerous tests for FDA pre-market approval and has held positions within the NHS, AstraZeneca, Qiagen and the Laboratory of the Government Chemist with a special focus on diagnostics. She is Board Chair at InvenireX, a non-executive director (NED) at Bionow, a life sciences membership organisation, and a former NED at Arctic Zymes. She advises several small businesses on their diagnostic strategy. Jane earned her MSc at Manchester Metropolitan University and her BSc in biochemistry at Manchester University.
- Timothy A. Yap, MBBS, PhD – Vice President and Head of Clinical Development, Therapeutics Discovery Division, MD Anderson Cancer Center: Dr. Yap is a Medical Oncologist and the Ransom Horne, Jr. Endowed Professor for Cancer Research. His research focuses on the first-in-human and combinatorial development of molecularly targeted agents and immunotherapies. He specializes in accelerating these agents through clinical studies using novel predictive and pharmacodynamic biomarkers. Dr. Yap received his PhD in Molecular Pharmacology from the Institute of Cancer Research and earned his medical degree from Imperial College London.
About intoDNA
intoDNA is a precision medicine company pioneering functional biomarkers that enable direct measurement of DNA damage and DNA repair pathway activity. Through its proprietary STRIDE® platform, the company provides ultra-sensitive, in situ detection and quantification of DNA damage response biology, delivering functional insight that cannot be inferred from genomic sequencing alone. The STRIDE platform supports biopharma research and translational development today, while the platform advances toward future diagnostic and companion diagnostic applications. As part of its platform, intoDNA is developing dSTRIDE™-HR, a functional homologous recombination deficiency (HRD) assay designed to directly measure DNA repair pathway activity within tumor tissue. By delivering decision-grade functional biomarkers that improve patient stratification, reduce development risk, and accelerate timelines, intoDNA enables more efficient drug development and more precise clinical care. For more information about intoDNA, please visit intoDNA.com, and follow us on LinkedIn.
Media Contact
Megan Prock McGrath
CTD Comms, LLC
[email protected]